57 results on '"Giovannetti, E."'
Search Results
2. 18F-Prostate-Specific Membrane Antigen PET/CT as a Potential Novel Imaging Modality for Pancreatic Cancer (PANSCAN-2): A Phase I/II Study
3. Bile Microbiome Signatures as Biomarkers for Differentiating Pancreatic Ductal Adenocarcinoma from Benign Disease
4. MicroRNAs as Bile Based Biomarkers for Pancreaticobiliary Cancers
5. Unravelling the impact of exosomes in pancreatic cancer metastasis through a new organotypic-liver slide culture system
6. Updates on the biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity
7. Modulation of RNA splicing as a novel strategy against pancreatic cancer
8. A combination of the proteins plasma thrombospondin-2 and CA19-9 improves the diagnosis of pancreatic cancer and distal cholangiocarcinoma
9. The biology of regulatory pathways of miRNAs, mRNAs and proteins unravels a specific -omics network in tumor-educated platelets from pancreatic cancer patients
10. Blood platelet RNA yields a new diagnostic prospective for accurate detection and staging of pancreatic ductal adenocarcinoma
11. Co-expression analysis of proteomics data reveal tumor biology and prognostic biomarkers for pancreatic ductal adenocarcinoma
12. 470P Anti-tumor mechanisms of rigosertib in colorectal cancer
13. Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
14. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract
15. Phosphoproteome networks identify focal adhesion kinase as a new drug target that can be exploited in synergistic combination with paclitaxel
16. Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX in advanced pancreatic ductal adenocarcinoma
17. Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment
18. Circulating microRNAs discriminate cholangiocarcinoma from pancreatic cancer
19. Platelet RNA yields a new diagnostic test for pancreatic cancer: a multicenter cohort
20. PO-042 Targeting hypoxic pancreatic cancer cells with glucose conjugated lactate dehydrogenase inhibitor NHI-Glc-2
21. PO-269 Development of a fluorescence in situ hybridization (FISH) method for detection of intra-tumour bacteria involved in pancreatic cancer chemoresistance
22. PO-278 Assessment of the influence of stellate cells on primary pancreatic cancer cell growth and drug resistance in a spheroid model: MET inhibitors to the rescue
23. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools
24. Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma
25. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies
26. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer
27. NOTCH2 and PTP4A3 gene copy number alterations are associated with prognosis and support novel therapeutic strategies for malignant pleural mesothelioma
28. Phospho-Akt: a potential resistance marker to chemotherapy and therapy-target to restore sensitivity in pancreatic cancer
29. A phosphoproteomic analysis of pancreatic cancer for therapy response prediction
30. Circulating micrornas as dynamic biomarkers of disease progression during folfirinox therapy in unresectable pancreatic ductal adenocarcinoma (pdac)
31. MiR-21 expression as prognostic biomarker in extrahepatic but not intrahepatic radically resected cholangiocarcinomas
32. 219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy
33. 200 The influence of different cMET and EGFR backgrounds on the cytotoxicity of cMET and EGFR small molecule inhibitors in vitro
34. 347 Can a link between the EGFR and cMET pathway in non-small cell lung cancer explain resistance against targeted therapies and open new therapeutic opportunities?
35. Tivantinib-Gemcitabine: Pharmacological Rational for a New Combination in Pancreatic Cancer
36. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
37. Prognostic factors in gemcitabine/cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back
38. Preclinical emergence of novel lactate dehydrogenase inhibitors as potent antitumor agents in hypoxic models of pancreatic cancer: Molecular mechanisms underlying their synergistic interaction with gemcitabine
39. Gemcitabine – Ukrain combination affects MMP9 expression in primary pancreatic adenocarcinoma cell cultures (PPCCs)
40. Significant Association Between Vegf-A and ABCB1 Polymorphisms and Survival in Metastatic Pancreatic Adenocarcinoma (MPA) Patients (PTS) Treated with Maintenance Sunitinib (MS)
41. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
42. “The only thing I know is that I know nothing”: 5-fluorouracil in human milk
43. 6639 POSTER Polymorphisms Associated With the Clinical Outcome of Biliary Tract Cancer (BTC) Patients Treated With the Epirubicin, Cisplatin and Capecitabine (ECX) Regimen
44. Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment
45. 46 IS BCRP EXPRESSION AND LOCALIZATION REGULATED BY EGFR PATHWAY IN NSCLC CELLS?
46. New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma
47. Early warning response of Posidonia oceanica epiphyte community to environmental alterations (Ligurian Sea, NW Mediterranean)
48. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry
49. OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib
50. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.